The FDA has approved pirtobrutinib (Jaypirca) monotherapy as a treatment for adults with previously untreated chronic ...
Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with ...
In a conversation with CancerNetwork ® at the 23rd Annual International Myeloma Society (IMS) Meeting & Exposition, Jeffrey V. Matous, MD, discussed the feasibility of standardiz ...
Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across ...
Patient enrollment of the phase 3 IDeate-Lung02 trial assessing I-DXd vs chemotherapy in relapsed ES-SCLC will continue ...
Hall, MD, professor and chair of radiation oncology at the Medical College of Wisconsin and medical director of Froedtert ...
Agarwal presented the TALAPRO-3 results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Agarwal ...
Resection combined with cesium-131 collagen tile-based radiation therapy (TBRT; GammaTile) significantly improved time to ...
At 8 years, SBRT and radical prostatectomy had similar disease control in the PACE-A trial, with less urinary incontinence ...
Ethan B. Ludmir, MD, explains why advanced radiation techniques like protons fit nonoperative cholangiocarcinoma better than ...
Elizabeth Thompson, MD, discusses pediatric cancer, proton therapy, and her work as a peer reviewer for CURiE. In an ...
Intensity-modulated proton therapy (IMPT) allows radiation oncologists to limit the dose to organs surrounding the prostate. That property may be particularly relevant for patients with prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results